Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.
Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.
The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.
Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.
The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.
For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.
Castle Biosciences (Nasdaq: CSTL), a healthcare company specializing in innovative diagnostic tests, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's executive management will deliver a corporate overview on Wednesday, Dec. 4, 2024, at 10:50 a.m. Eastern time.
A live audio webcast of the presentation will be accessible through Castle Biosciences' investor relations website. Additionally, a replay of the presentation will be made available after the live broadcast concludes.
Castle Biosciences (CSTL) has been named a Houston Top Workplace for 2024 by the Houston Chronicle, marking its fourth consecutive year receiving this recognition. The company also earned three additional Culture Excellence awards for Employee Appreciation, Employee Well-Being, and Professional Development.
The recognition is based on anonymous employee feedback collected through Energage's third-party survey, which measures various aspects of employee experience including feeling respected, supported, and empowered. Castle has accumulated a total of 12 Top Workplaces awards for 2024, including regional awards for Houston and Arizona, and ten national awards. The company ranked 28th among 370 companies in the Top Workplaces USA category and fourth out of 95 firms in the Healthcare Industry category.
Castle Biosciences (Nasdaq: CSTL) will present new data on its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology 61st Annual Meeting in Chicago, November 7-10. The presentations will showcase the clinical performance of these tests in risk-stratification for patients with confirmed or suspected melanoma.
Two posters will be presented by Dr. Etan Marks during a poster defense session on November 9. The first poster focuses on the integrated 31-gene expression profile test for melanoma recurrence risk stratification, while the second discusses statistical methods for assessing the diagnostic performance of the 23-gene expression profile test for cutaneous melanocytic neoplasms.
Castle Biosciences, a precision medicine company, announced a milestone for its TissueCypher Barrett’s Esophagus test, surpassing 25,000 test reports delivered since acquiring the test in late 2021. TissueCypher predicts the risk of progression from Barrett’s esophagus (BE) to esophageal cancer. BE is the only known precursor to esophageal adenocarcinoma, a rapidly increasing cancer in the U.S. with a five-year survival rate of 22%. TissueCypher, supported by 14 peer-reviewed studies, outperforms traditional pathology diagnoses, providing personalized risk scores and actionable insights. This test can help clinicians make informed decisions, potentially preventing esophageal cancer through tailored surveillance and intervention strategies.
Castle Biosciences presented new data from their DECIDE study showing that their DecisionDx-Melanoma test reduced unnecessary sentinel lymph node biopsy (SLNB) procedures by 25%. The study, presented at Dermato-Onco2024, included 471 patients with T1-T2a melanoma tumors. Among patients who underwent SLNB, none with low-risk DecisionDx-Melanoma results (predicted risk <5%) had positive nodes, while 9.8% of those with predicted risk ≥5% showed positive results. The test integrates tumor biology with clinicopathologic factors to predict SLN positivity risk, helping physicians and patients make informed decisions about SLNB procedures.
Castle Biosciences (CSTL) reported strong Q3 2024 financial results with revenue increasing 39% to $85.8 million compared to Q3 2023. Total test reports grew 41% to 26,010. The company raised its full-year 2024 revenue guidance to $320-330 million from $275-300 million. Q3 highlights include a gross margin of 79%, net income of $2.3 million, and Adjusted EBITDA of $21.6 million. Notable growth was seen across multiple tests, with TissueCypher® Barrett's Esophagus test reports increasing 115% and IDgenetix® test reports up 81%. The company's cash position stood at $279.8 million as of September 30, 2024.
Castle Biosciences (CSTL) presented new data at ACG 2024 showing their TissueCypher® test can significantly reduce healthcare costs and improve quality of life for Barrett's esophagus (BE) patients. Using a simulation model of 10,000 patients, the study demonstrated a $17M decrease in BE management costs when patients identified by TissueCypher as high-risk received endoscopic eradication therapy. The test reduced esophageal cancer progression by 58.4% and EAC-related death by 59.6%. The abstract received a Presidential Poster Award, an honor given to only 5-7% of submissions for outstanding research.
Castle Biosciences (CSTL) has announced its executive management's participation in three upcoming investor conferences in November 2024. The company will present overviews at the Guggenheim Securities Healthcare Innovation Conference on Nov. 11 at 2:30 p.m. ET and the Stephens 26th Annual Investment Conference on Nov. 20 at 9:00 a.m. ET. Additionally, Castle will be available for one-on-one investor meetings during the UBS Global Healthcare Conference on Nov. 12. Live audio webcasts of the presentations will be accessible through Castle's investor relations website, with replays available after the events.
Castle Biosciences presented new data at the 2024 ASDS Annual Meeting supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests in guiding skin cancer treatment decisions. The CONNECTION study showed that using DecisionDx-Melanoma could reduce unnecessary sentinel lymph node biopsies (SLNB) by up to 64% in patients with T1 melanoma tumors, while maintaining high survival rates. For squamous cell carcinoma (SCC), DecisionDx-SCC demonstrated utility in guiding radiologic surveillance imaging decisions for patients with stage T2b tumors. The test identified low-risk patients who could safely defer imaging and higher-risk patients who may benefit from imaging for early detection of disease progression.
Castle Biosciences announced two recent studies supporting the clinical need for its MyPath® Melanoma gene expression profile (GEP) test. The studies, published in the Journal of Cutaneous Pathology and Melanoma Management, demonstrate:
- Significant disagreement in diagnosing melanocytic lesions using pathology alone
- Variability in surgical management among dermatologists
- Risk-aligned changes and increased confidence in decisions resulting from GEP testing
Key findings include:
- 24% of suspicious lesions had differing diagnoses by nine board-certified dermatopathologists
- 84.2% of clinicians decreased recommended surgical margins with benign GEP results
- 100% of clinicians increased surgical excision recommendations with malignant GEP results
- Overall increase in patient management plan confidence with GEP results
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
What does Castle Biosciences specialize in?
When was Castle Biosciences founded?
What types of cancer does Castle Biosciences have tests for?
What are some of Castle Biosciences' notable products?
Is Castle Biosciences involved in research for new diagnostic tests?
Where can I find more information about Castle Biosciences and its products?
What is the primary mission of Castle Biosciences?
Does Castle Biosciences collaborate with other entities?
What is Castle Biosciences' financial condition?
How does Castle Biosciences contribute to cancer care?
